



Kongeriget Danmark

Patent application No.: PA 2003 01824
Date of filing: 10 December 2003
Applicant:
(Name and address) Novozymes A/S
Krogshøjvej 36
DK-2880 Bagsværd
Denmark

Title: A cell with improved secretion mediated by MrgA protein or homologue

IPC: -

This is to certify that the attached documents are exact copies of the above mentioned patent application as originally filed.



Patent- og Varemærkestyrelsen
Økonomi- og Erhvervsministeriet

07 January 2005

Susanne Morsing
Susanne Morsing

TITLE: A cell with improved secretion mediated by MrgA protein or homologue

10 DEC. 2003

Modtaget

FIELD OF THE INVENTION

In the industrial production of secreted polypeptides it is of interest to achieve a product
5 yield as high as possible. Accordingly, it is highly desirable to remove any potential bottlenecks
from the secretory machinery of production cells. To this end it is well-known that it can be
advantageous to overexpress one or more gene(s) encoding protein(s) involved with secretion,
e.g., PrsA protein or functional homologues thereof. The present invention relates to a cell
which overexpresses MrgA protein or functional MrgA protein homologue.

BACKGROUND OF THE INVENTION

The MrgA protein of *Bacillus subtilis* was originally classified as a Dps(PexB)
homologue, encoded by a metalloregulated oxidative-stress gene (metallo regulated gene)
mrgA. One purported function of the MrgA protein *in B. subtilis* is to bind DNA under conditions
15 of oxidative stress and to protect the DNA against damage (Chen L, Helmann JD. 1995.
Bacillus subtilis MrgA is a Dps(PexB) homologue: evidence for metalloregulation of an
oxidative stress gene. Mol Microbiol 18: 295-300).

A *B. subtilis mrgA* deletion mutant only had a somewhat reduced overall level of
secreted proteins, and it was therefore broadly concluded that MrgA is not involved in protein
20 secretion in *B. subtilis*, (van Wely KH, Swaving J, Klein M, Freudl R, Driessen AJ. 2000. The
carboxyl terminus of the Bacillus subtilis SecA is dispensable for protein secretion and viability.
Microbiology 146: 2573-81).

However, the present inventors have found, as demonstrated herein, that MrgA *is* in
fact involved in secretion in *Bacillus*, and that a higher expression of *mrgA* leads to a higher
25 secretion of an exoenzyme, exemplified below by improved secretion of a heterologous alpha-
amylase.

SUMMARY OF THE INVENTION

Severe secretion stress was imposed on a *Bacillus subtilis* cell by overexpressing an
30 exoenzyme, the alpha-amylase AmyQ of *Bacillus amyloliquefaciens*, encoded by a plasmid-
borne constitutively expressed gene in the cell. DNA microarray analyses revealed an
increased expression of the general stress protein *mrgA* as a response to the imposed
'secretion stress.

The *mrgA* gene was amplified by PCR from the chromosome of *B. subtilis*. Three PCR
35 reactions were carried out with three different upstream PCR primers, each comprising the
sequence of a synthetic constitutive promoter of different strength. The three amplified PCR
fragments were integrated into the chromosome of individual *B. subtilis* strains, resulting in

three recombinant strains, each expressing *mrgA* from the native locus, and from the integrated *mrgA* copy, which was transcribed from the synthetic promoter.

The three strains overexpressing *mrgA*, and a corresponding control strain, were then transformed with the plasmid pKTH10, which carries and constitutively overexpresses the gene encoding the alpha-amylase AmyQ of *B. amyloliquefaciens*.

The yields of secreted AmyQ amylase from the transformed strains were determined after 1 weeks cultivation in 200 ml BPX culture flasks. For each of the three MrgA overexpressing strains, and the control strain, three independent isolates were analysed in triplicate to determine the amylase yields. The yields of secreted amylase from the MrgA overexpressing strains were 27% - 44% higher than the yield from the control strain.

Accordingly, in a first aspect the invention relates to a progeny cell derived from a parent cell, wherein

- a) the progeny cell comprises at least one gene encoding MrgA protein or a functional homologue thereof and/or a DNA segment operably linked with the encoding gene, wherein said gene and/or DNA segment is manipulated with respect to the parent cell;
- b) the progeny cell comprises two or more copies of a gene encoding MrgA protein or a functional homologue thereof; or
- c) the progeny cell is mutated with respect to the parent cell; whereby the progeny cell produces greater amounts of MrgA protein or a functional homologue thereof than the parent cell.

In the present context, a functional homologue of the MrgA protein is a protein, which when expressed at a higher level in a cell, leads to an increased secretion of an exoenzyme, such as an alpha-amylase, when compared with an otherwise identical cell with normal expression of the MrgA functional homologue cultivated under essentially identical conditions.

In addition, the functional homologue of the MrgA protein shares an amino acid sequence identity with the MrgA protein of at least 50%, preferably 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, or most preferably 99% when aligned as described above.

A second aspect of the invention relates to a method for enhancing secretion of an exoprotein of interest, the method comprising expressing said exoprotein in a cell according to the first aspect.

A third aspect of the invention relates to a method for producing a cell as defined in the first aspect useful for production of an exoprotein of interest, said method comprising a step of manipulating a cell to increase the expression of MrgA protein or functional homologue thereof.

In a fourth aspect the invention relates to a method for producing an exoprotein of interest, comprising the steps of:

- a) cultivating a cell as defined in the first aspect; and
- b) recovering the exoprotein.

In a final aspect the invention relates to the use of MrgA-protein or a functional homologue thereof in a method for enhancing secretion of an exoprotein by manipulating or mutating a cell to express greater amounts of MrgA protein or functional homologue thereof than the non-manipulated or non-mutated cell.

5

DEFINITIONS

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook et al., 1989") DNA Cloning: A Practical Approach, Volumes I and II /D.N. Glover ed. 1985); Oligonucleotide Synthesis (M.J. Gait ed. 1984); Nucleic Acid Hybridization (B.D. Hames & S.J. Higgins eds (1985)); Transcription And Translation (B.D. Hames & S.J. Higgins, eds. (1984)); Animal Cell Culture (R.I. Freshney, ed. (1986)); Immobilized Cells And Enzymes (IRL Press, (1986)); B. Perbal, A Practical Guide To Molecular Cloning (1984).

A "polynucleotide" is a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized in vitro, or prepared from a combination of natural and synthetic molecules.

A "nucleic acid molecule" or "nucleotide sequence" refers to the phosphate ester polymeric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules") or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; "DNA molecules") in either single stranded form, or a double-stranded helix. Double stranded DNA-DNA, DNA-RNA and RNA-RNA helices are possible. The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary or quaternary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear or circular DNA molecules (e.g., restriction fragments), plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA). A "recombinant DNA molecule" is a DNA molecule that has undergone a molecular biological manipulation.

A nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and

THIS PAGE BLANK (USPTO)

solution ionic strength (see Sambrook et al., supra). The conditions of temperature and ionic strength determine the "stringency" of the hybridization.

For purposes of the present invention, hybridization indicates that the nucleotide sequence hybridizes to a labeled polynucleotide probe which hybridizes to the nucleotide sequence shown in SEQ ID NO:1 under very low to very high stringency conditions. Molecules to which the polynucleotide probe hybridizes under these conditions may be detected using X-ray film or by any other method known in the art. Whenever the term "polynucleotide probe" is used in the present context, it is to be understood that such a probe contains at least 15 nucleotides.

In an interesting embodiment, the polynucleotide probe is the complementary strand of a fragment of at least 15 nucleotides of SEQ ID NO:1. In another interesting embodiment, the polynucleotide probe is a fragment of at least 15 nucleotides of the complementary strand of any nucleotide sequence which encodes the polypeptide of SEQ ID NO:2. In a further interesting embodiment, the polynucleotide probe is the complementary strand of SEQ ID NO:1. In a still further interesting embodiment, the polynucleotide probe is the complementary strand of the mature polypeptide coding region of SEQ ID NO:1.

For long probes of at least 100 nucleotides in length, very low to very high stringency conditions are defined as prehybridization and hybridization at 42°C in 5X SSPE, 1.0% SDS, 5X Denhardt's solution, 100 µg/ml sheared and denatured salmon sperm DNA, following standard Southern blotting procedures. Preferably, the long probes of at least 100 nucleotides do not contain more than 1000 nucleotides. For long probes of at least 100 nucleotides in length, the carrier material is finally washed three times each for 15 minutes using 2 x SSC, 0.1% SDS at 42°C (very low stringency), preferably washed three times each for 15 minutes using 0.5 x SSC, 0.1% SDS at 42°C (low stringency), more preferably washed three times each for 15 minutes using 0.2 x SSC, 0.1% SDS at 42°C (medium stringency), even more preferably washed three times each for 15 minutes using 0.2 x SSC, 0.1% SDS at 55°C (medium-high stringency), most preferably washed three times each for 15 minutes using 0.1 x SSC, 0.1% SDS at 60°C (high stringency), in particular washed three times each for 15 minutes using 0.1 x SSC, 0.1% SDS at 68°C (very high stringency).

Although not particularly preferred, it is contemplated that shorter probes, e.g. probes which are from about 15 to 99 nucleotides in length, such as from about 15 to about 70 nucleotides in length, may be also be used. For such short probes, stringency conditions are defined as prehybridization, hybridization, and washing post-hybridization at 5°C to 10°C below the calculated T_m using the calculation according to Bolton and McCarthy (1962, Proceedings of the National Academy of Sciences USA 48:1390) in 0.9 M NaCl, 0.09 M Tris-HCl pH 7.6, 6 mM EDTA, 0.5% NP-40, 1X Denhardt's solution, 1 mM sodium pyrophosphate, 1 mM sodium monobasic phosphate, 0.1 mM ATP, and 0.2 mg of yeast RNA per ml following standard Southern blotting procedures.

For short probes which are about 15 nucleotides to 99 nucleotides in length, the carrier material is washed once in 6X SSC plus 0.1% SDS for 15 minutes and twice each for 15 minutes using 6X SSC at 5°C to 10°C below the calculated T_m .

A DNA "coding sequence" or an "open reading frame (ORF)" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in a cell in vitro or in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. If the coding sequence is intended for expression in a eukaryotic cell, a polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

An expression vector is a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription. Such additional segments may include promoter and terminator sequences, and optionally one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, and the like. Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, terminators, and the like, that provide for the expression of a coding sequence in a host cell. In eukaryotic cells, polyadenylation signals are control sequences.

A "secretory signal sequence" is a DNA sequence that encodes a polypeptide (a "secretory peptide" that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.

The term "promoter" is used herein for its art-recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes.

A chromosomal gene is rendered non-functional if the polypeptide that the gene encodes can no longer be expressed in a functional form. Such non-functionality of a gene can be induced by a wide variety of genetic manipulations as known in the art, some of which are described in Sambrook et al. *vide supra*. Partial deletions within the ORF of a gene will often render the gene non-functional, as will mutations.

The term "an expressible copy of a chromosomal gene" is used herein as meaning a copy of the ORF of a chromosomal gene, wherein the ORF can be expressed to produce a

fully functional gene product. The expressible copy may not be transcribed from the native promoter of the chromosomal gene, it may instead be transcribed from a foreign or heterologous promoter, or it may indeed be promoterless and expressed only by transcriptional read-through from a gene present upstream of the 5' end of the ORF. Transcriptional read-through is intended to have the same meaning here as the generally recognized meaning in the art.

"Operably linked", when referring to DNA segments, indicates that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in the promoter and proceeds through the coding segment to the terminator.

A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then trans-RNA spliced and translated into the protein encoded by the coding sequence.

"Heterologous" DNA refers to DNA not naturally located in the cell, or in a chromosomal site of the cell. Preferably, the heterologous DNA includes a gene foreign to the cell.

As used herein the term "nucleic acid construct" is intended to indicate any nucleic acid molecule of cDNA, genomic DNA, synthetic DNA or RNA origin. The term "construct" is intended to indicate a nucleic acid segment which may be single- or double-stranded, and which may be based on a complete or partial naturally occurring nucleotide sequence encoding a polypeptide of interest. The construct may optionally contain other nucleic acid segments.

The nucleic acid construct of the invention encoding the polypeptide of the invention may suitably be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA sequences coding for all or part of the polypeptide by hybridization using synthetic oligonucleotide probes in accordance with standard techniques (cf. Sambrook et al., *supra*).

The nucleic acid construct of the invention encoding the polypeptide may also be prepared synthetically by established standard methods, e.g. the phosphoramidite method described by Beaucage and Caruthers, *Tetrahedron Letters* 22 (1981), 1859 - 1869, or the method described by Matthes et al., *EMBO Journal* 3 (1984), 801 - 805. According to the phosphoramidite method, oligonucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed, ligated and cloned in suitable vectors.

Furthermore, the nucleic acid construct may be of mixed synthetic and genomic, mixed synthetic and cDNA or mixed genomic and cDNA origin prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate), the fragments corresponding to various parts of the entire nucleic acid construct, in accordance with standard techniques. The nucleic acid construct may also be prepared by polymerase chain reaction using specific primers, for instance as described in US 4,683,202 or Saiki et al., *Science* 239 (1988), 487 - 491.

The term nucleic acid construct may be synonymous with the term "expression cassette" when the nucleic acid construct contains the control sequences necessary for expression of a coding sequence of the present invention

The term "control sequences" is defined herein to include all components which are necessary or advantageous for expression of the coding sequence of the nucleic acid sequence. Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, a polyadenylation sequence, a propeptide sequence, a promoter, a signal sequence, and a transcription terminator. At a minimum, the control sequences include a promoter, and transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleic acid sequence encoding a polypeptide.

The control sequence may be an appropriate promoter sequence, a nucleic acid sequence which is recognized by a host cell for expression of the nucleic acid sequence. The promoter sequence contains transcription and translation control sequences which mediate the expression of the polypeptide. The promoter may be any nucleic acid sequence which shows transcriptional activity in the host cell of choice and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.

The control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleic acid sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present invention.

The control sequence may also be a polyadenylation sequence, a sequence which is operably linked to the 3' terminus of the nucleic acid sequence and which, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence which is functional in the host cell of choice may be used in the present invention.

The control sequence may also be a signal peptide coding region, which codes for an amino acid sequence linked to the amino terminus of the polypeptide which can direct the expressed polypeptide into the cell's secretory pathway of the host cell. The 5' end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region which encodes the secreted polypeptide. Alternatively, the 5' end of the coding sequence may contain a signal peptide coding region which is foreign to that portion of the coding sequence which encodes the secreted polypeptide. A foreign signal peptide coding region may be required where the coding sequence does not normally contain a signal peptide coding region. Alternatively, the foreign signal peptide coding region may simply replace the natural signal peptide coding region in order to obtain enhanced secretion of the exoprotein relative to the

natural signal peptide coding region normally associated with the coding sequence. The signal peptide coding region may be obtained from a glucoamylase or an amylase gene from an *Aspergillus* species, a lipase or proteinase gene from a *Rhizomucor* species, the gene for the alpha-factor from *Saccharomyces cerevisiae*, an amylase or a protease gene from a *Bacillus* species, or the calf preprochymosin gene. However, any signal peptide coding region capable of directing the expressed polypeptide into the secretory pathway of a host cell of choice may be used in the present invention.

The control sequence may also be a propeptide coding region, which codes for an amino acid sequence positioned at the amino terminus of a polypeptide. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the *Bacillus subtilis* alkaline protease gene (*aprE*), the *Bacillus subtilis* neutral protease gene (*nprT*), the *Saccharomyces cerevisiae* alpha-factor gene, or the *Myceliophthora thermophilum* laccase gene (WO 95/33836).

It may also be desirable to add regulatory sequences which allow the regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems would include the *lac*, *tac*, and *trp* operator systems. In yeast, the *ADH2* system or *GAL1* system may be used. Other examples of regulatory sequences are those which allow for gene amplification. In eukaryotic systems, these include the dihydrofolate reductase gene which is amplified in the presence of methotrexate, and the metallothionein genes which are amplified with heavy metals. In these cases, the nucleic acid sequence encoding the polypeptide would be placed in tandem with the regulatory sequence.

Examples of suitable promoters for directing the transcription of the gene(s) of the present invention, especially in a bacterial host cell, are the promoters obtained from the *E. coli* *lac* operon, the *Streptomyces coelicolor* agarase gene (*dagA*), the *Bacillus subtilis* levansucrase gene (*sacB*), the *Bacillus subtilis* alkaline protease gene, the *Bacillus licheniformis* alpha-amylase gene (*amyL*), the *Bacillus stearothermophilus* maltogenic amylase gene (*amyM*), the *Bacillus amyloliquefaciens* alpha-amylase gene (*amyQ*), the *Bacillus amyloliquefaciens* BAN amylase gene, the *Bacillus licheniformis* penicillinase gene (*penP*), the *Bacillus subtilis* *xylA* and *xylB* genes, and the prokaryotic beta-lactamase gene (Villa-Kamaroff et al., 1978, Proceedings of the National Academy of Sciences USA 75:3727-3731), as well as the *tac* promoter (DeBoer et al., 1983, Proceedings of the National Academy of Sciences USA 80:21-25). Further promoters are described in "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; and in Sambrook et al., 1989, supra.

An effective signal peptide coding region for bacterial host cells is the signal peptide coding region obtained from the maltogenic amylase gene from *Bacillus* NCIB 11837, the *Bacillus stearothermophilus* alpha-amylase gene, the *Bacillus licheniformis* subtilisin gene, the *Bacillus licheniformis* beta-lactamase gene, the *Bacillus stearothermophilus* neutral proteases genes (nprT, nprS, nprM), and the *Bacillus subtilis* PrsA gene. Further signal peptides are described by Simonen and Palva, 1993, Microbiological Reviews 57:109-137.

The present invention also relates to recombinant expression vectors comprising a nucleic acid sequence of the present invention, a promoter, and transcriptional and translational stop signals. The various nucleic acid and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the nucleic acid sequence encoding the polypeptide at such sites. Alternatively, the nucleic acid sequence of the present invention may be expressed by inserting the nucleic acid sequence or a nucleic acid construct comprising the sequence into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression, and possibly secretion.

The recombinant expression vector may be any vector (e.g., a plasmid or virus) which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the nucleic acid sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids. The vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. The vector system may be a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon.

The vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like.

Antibiotic selectable markers confer antibiotic resistance to such antibiotics as ampicillin, kanamycin, chloramphenicol, tetracycline, neomycin, hygromycin or methotrexate. Suitable markers for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3.

The vectors of the present invention preferably contain an element(s) that permits stable integration of the vector, or of a smaller part of the vector, into the host cell genome or autonomous replication of the vector in the cell independent of the genome of the cell.

5 The vectors, or smaller parts of the vectors such as amplification units of the present invention, may be integrated into the host cell genome when introduced into a host cell. For chromosomal integration, the vector may rely on the nucleic acid sequence encoding the polypeptide or any other element of the vector for stable integration of the vector into the genome by homologous or nonhomologous recombination.

10 Alternatively, the vector may contain additional nucleic acid sequences for directing integration by homologous recombination into the genome of the host cell. The additional nucleic acid sequences enable the vector to be integrated into the host cell genome at a precise location(s) in the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should preferably contain a sufficient number of nucleic acids, such as 100 to 1,500 base pairs, preferably 400 to 1,500 base pairs, and most
15 preferably 800 to 1,500 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding nucleic acid sequences; specific examples of encoding sequences suitable for site-specific
20 integration by homologous recombination are given in WO 02/00907 (Novozymes, Denmark), which is hereby incorporated by reference in its totality.

On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination. These nucleic acid sequences may be any sequence that is homologous with a target sequence in the genome of the host cell, and, furthermore, may be
25 non-encoding or encoding sequences. The copy number of a vector, an expression cassette, an amplification unit, a gene or indeed any defined nucleotide sequence is the number of identical copies that are present in a host cell at any time. A gene or another defined chromosomal nucleotide sequence may be present in one, two, or more copies on the chromosome. An autonomously replicating vector may be present in one, or several hundred
30 copies per host cell.

An amplification unit of the invention is a nucleotide sequence that can integrate into the chromosome of a host cell, whereupon it can increase in number of chromosomally
integrated copies by duplication or multiplication. The unit comprises an expression cassette as defined herein comprising at least one copy of a gene of interest and an expressible copy
35 of a chromosomal gene, as defined herein, of the host cell. When the amplification unit is integrated into the chromosome of a host cell, it is defined as that particular region of the chromosome which is prone to being duplicated by homologous recombination between two directly repeated regions of DNA. The precise border of the amplification unit with respect to

the flanking DNA is thus defined functionally, since the duplication process may indeed duplicate parts of the DNA which was introduced into the chromosome as well as parts of the endogenous chromosome itself, depending on the exact site of recombination within the repeated regions. This principle is illustrated in Janni re *et al.* (1985, Stable gene amplification
5 in the chromosome of *Bacillus subtilis*. Gene, 40: 47-55), which is incorporated herein by reference.

For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19,
10 pACYC177, pACYC184, pUB110, pE194, pTA1060, and pAMBeta1. Examples of origin of replications for use in a yeast host cell are the 2 micron origin of replication, the combination of CEN6 and ARS4, and the combination of CEN3 and ARS1. The origin of replication may be one having a mutation which makes its functioning temperature-sensitive in the host cell (see, e.g., Ehrlich, 1978, Proceedings of the National Academy of Sciences USA 75:1433).

15 The present invention also relates to recombinant host cells, comprising a nucleic acid sequence of the invention, which are advantageously used in the recombinant production of the polypeptides. The term "host cell" encompasses any progeny of a parent cell which is not identical to the parent cell due to mutations that occur during replication.

The cell is preferably transformed with a vector comprising a nucleic acid sequence of
20 the invention followed by integration of the vector into the host chromosome. "Transformation" means introducing a vector comprising a nucleic acid sequence of the present invention into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector. Integration is generally considered to be an advantage as the nucleic acid sequence is more likely to be stably maintained in the cell. Integration of the
25 vector into the host chromosome may occur by homologous or non-homologous recombination as described above.

The transformation of a bacterial host cell may, for instance, be effected by protoplast transformation (see, e.g., Chang and Cohen, 1979, Molecular General Genetics 168:111-115), by using competent cells (see, e.g., Young and Spizizin, 1961, Journal of Bacteriology 81:823-
30 829, or Dubnar and Davidoff-Abelson, 1971, Journal of Molecular Biology 56:209-221), by electroporation (see, e.g., Shigekawa and Dower, 1988, Biotechniques 6:742-751), or by conjugation (see, e.g., Koehler and Thorne, 1987, Journal of Bacteriology 169:5771-5278).

The transformed or transfected host cells described above are cultured in a suitable nutrient medium under conditions permitting the expression of the desired polypeptide, after
35 which the resulting polypeptide is recovered from the cells, or the culture broth.

The medium used to culture the cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to

published recipes (e.g. in catalogues of the American Type Culture Collection). The media are prepared using procedures known in the art (see, e.g., references for bacteria and yeast; Bennett, J.W. and LaSure, L., editors, *More Gene Manipulations in Fungi*, Academic Press, CA, 1991).

- 5 If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it is recovered from cell lysates. The polypeptide are recovered from the culture medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt, e.g.
- 10 ammonium sulphate, purification by a variety of chromatographic procedures, e.g. ion exchange chromatography, gel filtration chromatography, affinity chromatography, or the like, dependent on the type of polypeptide in question.

- The polypeptides may be detected using methods known in the art that are specific for the polypeptides. These detection methods may include use of specific antibodies, formation
- 15 of an enzyme product, or disappearance of an enzyme substrate. For example, an enzyme assay may be used to determine the activity of the polypeptide.

- The polypeptides of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g.,
- 20 preparative isoelectric focusing (IEF), differential solubility (e.g., ammonium sulfate precipitation), or extraction (see, e.g., *Protein Purification*, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).

- In the present context, the term "substantially pure polypeptide" means a polypeptide preparation which contains at the most 10% by weight of other polypeptide material with which
- 25 it is natively associated (lower percentages of other polypeptide material are preferred, e.g. at the most 8% by weight, at the most 6% by weight, at the most 5% by weight, at the most 4% at the most 3% by weight, at the most 2% by weight, at the most 1% by weight, and at the most ½% by weight). Thus, it is preferred that the substantially pure polypeptide is at least 92% pure, i.e. that the polypeptide constitutes at least 92% by weight of the total polypeptide
- 30 material present in the preparation, and higher percentages are preferred such as at least 94% pure, at least 95% pure, at least 96% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99%, and at the most 99.5% pure. The polypeptides disclosed herein are preferably in a substantially pure form. In particular, it is preferred that the polypeptides disclosed herein are in "essentially pure form", i.e. that the polypeptide preparation is
- 35 essentially free of other polypeptide material with which it is natively associated. This can be accomplished, for example, by preparing the polypeptide by means of well-known recombinant methods. Herein, the term "substantially pure polypeptide" is synonymous with the terms "isolated polypeptide" and "polypeptide in isolated form".

In the present context, the homology between two amino acid sequences or between two nucleotide sequences is described by the parameter "identity". For purposes of the present invention, alignments of sequences and calculation of homology scores may be done using a full Smith-Waterman alignment, useful for both protein and DNA alignments. The default scoring matrices BLOSUM50 and the identity matrix are used for protein and DNA alignments respectively. The penalty for the first residue in a gap is -12 for proteins and -16 for DNA, while the penalty for additional residues in a gap is -2 for proteins and -4 for DNA. Alignment may be made with the FASTA package version v20u6 (W. R. Pearson and D. J. Lipman (1988), "Improved Tools for Biological Sequence Analysis", PNAS 85:2444-2448, and W. R. Pearson (1990) "Rapid and Sensitive Sequence Comparison with FASTP and FASTA", Methods in Enzymology, 183:63-98).

Multiple alignments of protein sequences may be made using "ClustalW" (Thompson, J.D., Higgins, D.G. and Gibson, T.J. (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, positions-specific gap penalties and weight matrix choice. Nucleic Acids Research, 22:4673-4680). Multiple alignment of DNA sequences may be done using the protein alignment as a template, replacing the amino acids with the corresponding codon from the DNA sequence.

In the present context, a functional homologue of the MrgA protein is a protein, which when expressed at a higher level in a cell, leads to an increased secretion of an exoenzyme, such as an alpha-amylase, when compared with a cell with normal expression of the MrgA functional homologue cultivated under essentially identical conditions. In addition, the functional homologue of the MrgA protein shares an amino acid sequence identity with the MrgA protein of at least 50%, preferably 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, or most preferably 99% when aligned as described above.

In the present context, the term "allelic variant" denotes any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences. An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene. Allelic variants are included in the present definition of functional homologues.

The MrgA protein or functional homologue thereof may be a wild-type protein identified and isolated from a natural source. Such wild-type proteins may be specifically screened for by standard techniques known in the art. Furthermore, the MrgA protein or functional homologue thereof may be prepared by the DNA shuffling technique, such as described in J.E. Ness et al. Nature Biotechnology 17, 893-896 (1999). Moreover, the MrgA protein or functional homologue thereof may be an artificial variant. Such artificial variants may be constructed by

THIS PAGE BLANK (USPTO)

standard techniques known in the art, such as by site-directed/random mutagenesis. In one embodiment of the invention, amino acid changes (in the artificial variant as well as in wild-type polypeptides) are of a minor nature, that is conservative amino acid substitutions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to about 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.

Examples of conservative substitutions are within the group of basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine, isoleucine, valine and methionine), aromatic amino acids (phenylalanine, tryptophan and tyrosine), and small amino acids (glycine, alanine, serine and threonine). Amino acid substitutions which do not generally alter the specific activity are known in the art and are described, for example, by H. Neurath and R.L. Hill, 1979, In, *The Proteins*, Academic Press, New York. The most commonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly as well as these in reverse.

It will be apparent to those skilled in the art that such modifications can be made outside the regions critical to the function of the molecule and still result in an active polypeptide. Amino acid residues essential to the activity of the polypeptide encoded by the nucleotide sequence of the invention, and therefore preferably not subject to modification, such as substitution, may be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (see, e.g., Cunningham and Wells, 1989, *Science* 244: 1081-1085). In the latter technique, mutations are introduced at every positively charged residue in the molecule, and the resultant mutant molecules are tested for activity to identify amino acid residues that are critical to the activity of the molecule. Sites of substrate-enzyme interaction can also be determined by analysis of the three-dimensional structure as determined by such techniques as nuclear magnetic resonance analysis, crystallography or photoaffinity labelling (see, e.g., de Vos et al., 1992, *Science* 255: 306-312; Smith et al., 1992, *Journal of Molecular Biology* 224: 899-904; Wlodaver et al., 1992, *FEBS Letters* 309: 59-64).

Moreover, a nucleotide sequence encoding a polypeptide of the present invention may be modified by introduction of nucleotide substitutions which do not give rise to another amino acid sequence of the polypeptide encoded by the nucleotide sequence, but which correspond to the codon usage of the host organism intended for production of the enzyme.

The introduction of a mutation into the nucleotide sequence to exchange one nucleotide for another nucleotide may be accomplished by site-directed mutagenesis using

any of the methods known in the art. Particularly useful is the procedure, which utilizes a supercoiled, double stranded DNA vector with an insert of interest and two synthetic primers containing the desired mutation. The oligonucleotide primers, each complementary to opposite strands of the vector, extend during temperature cycling by means of Pfu DNA polymerase.

- 5 On incorporation of the primers, a mutated plasmid containing staggered nicks is generated. Following temperature cycling, the product is treated with DpnI which is specific for methylated and hemimethylated DNA to digest the parental DNA template and to select for mutation-containing synthesized DNA. Other procedures known in the art may also be used. For a general description of nucleotide substitution, see, e.g., Ford et al., 1991, Protein Expression and Purification 2: 95-107.
- 10

DETAILED DESCRIPTION OF THE INVENTION

The first aspect of the invention relates to a progeny cell derived from a parent cell, wherein

- 15 a) the progeny cell comprises at least one gene encoding MrgA protein or a functional homologue thereof and/or a DNA segment operably linked with the encoding gene, wherein said gene and/or DNA segment is manipulated with respect to the parent cell;
- b) the progeny cell comprises two or more copies of a gene encoding MrgA protein or a functional homologue thereof; or
- 20 c) the progeny cell is mutated with respect to the parent cell;
- whereby the progeny cell produces greater amounts of MrgA protein or a functional homologue thereof than the parent cell.

The cell of the invention greater amounts of MrgA protein or a functional homologue thereof, than the parent cell. A comparison should be made by cultivating the cell of the invention as well as the parent cell under essentially identical conditions, and comparing the amount of MrgA protein by any standard method in the art. Preferably the cell of the invention produces at least 5% more MrgA than the parent, more preferably at least 10%, still more preferably at least 20%, and most preferably at least 50% more MrgA protein or a functional homologue thereof than the parent. Such overproduction may be accomplished by standard means known to the art, e.g., use of multicopy plasmids, multiple copies of the genes encoding MrgA or a functional homologue thereof, and/or the exoprotein of interest, in the chromosome of the host, combined with altering the regulatory elements to increase expression, e.g., use of strong promoter(s), use of multiple promoters, use of enhancers, and so forth.

25

30

As the inventors show herein, a cell of the first aspect is capable of secreting greater amounts of an exoprotein of interest than the corresponding parent cell, when both are cultivated under essentially identical conditions.

35

Accordingly, a preferred embodiment of the invention relates to the cell of the first aspect, which secretes greater amounts of an exoprotein of interest than the parent cell.

Preferably the cell of the invention secretes at least 5% more exoprotein than the parent, more preferably at least 10% more, still more preferably at least 20% more, and most preferably at least 50% more exoprotein than the parent. The amount of secreted exoprotein from each cell may be determined by any suitable assay in the art; a non-limiting example is shown below
 5 with the determination of secreted amounts of alpha-amylase.

The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source. The host cell may be a unicellular microorganism, e.g., a prokaryote, or a non-unicellular microorganism, e.g., a eukaryote. Useful unicellular cells are bacterial cells such as gram positive bacteria including, but not limited to, a *Bacillus* cell, e.g.,
 10 *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*; or a *Streptomyces* cell, e.g., *Streptomyces lividans* or *Streptomyces murinus*, or gram negative bacteria such as *E. coli* and *Pseudomonas sp.* In a preferred embodiment, the bacterial host cell is a *Bacillus lentus*,
 15 *Bacillus licheniformis*, *Bacillus stearothermophilus* or *Bacillus subtilis* cell. In one preferred embodiment, the bacterial host cell is a prokaryotic cell, preferably a Gram-positive prokaryotic cell, and more preferably the bacterial Gram positive cell is a species of the genus *Bacillus*, preferably selected from the group consisting of *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus lautus*,
 20 *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*.

A preferred embodiment relates to the cell of the invention, which is a bacterial cell, preferably a prokaryotic cell, more preferably a Gram-positive cell, and most preferably of the genus *Bacillus*; still more preferably it is of a species chosen from the group consisting of
 25 *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*.

The exoprotein of interest may be endogenous or exogenous to the host cell, it may be a homologous exoprotein, or a heterologous exoprotein.

A preferred embodiment relates to the cell, wherein said exoprotein is a protease, a lipase, a cutinase, an amylase, a galactosidase, a pullulanase, a cellulase, a glucose isomerase, a protein disulphide isomerase, a CGTase (cyclodextrin gluconotransferase), a phytase, a glucose oxidase, a glucosyl transferase, lactase, bilirubin oxidase, a xylanase, an antigenic microbial or protozoan protein, a bacterial protein toxin, a microbial surface protein,
 35 or a viral protein.

An evolutionary homologue of the MrgA protein, an allelic variant, an artificial variant, a shuffled variant, a species variant, and so forth, are all referred to as a "functional homologue"

or the MrgA protein in the present description, and the inventors envision that such functional homologue protein(s) will be equally effective in the cell of the invention.

Specifically, a preferred embodiment relates to the cell, wherein the MrgA protein or functional homologue thereof comprises an amino acid sequence which is at least 70% identical to the amino sequence shown in SEQ ID NO:2, preferably at least 75%, 80%, 85%, 90%, 95%, 97%, or even 99% identical to the amino sequence shown in SEQ ID NO:2.

Another preferred embodiment relates to the cell of the invention, wherein the MrgA protein or functional homologue thereof comprises or consists of the amino acid sequence shown in SEQ ID NO:2.

Still another preferred embodiment relates to the cell of the invention, which comprises at least one exogenous copy of a polynucleotide encoding MrgA protein or a functional homologue thereof comprising an amino acid sequence which is at least 70% identical to the amino sequence shown in SEQ ID NO:2, preferably at least 75%, 80%, 85%, 90%, 95%, 97%, or even 99% identical to the amino sequence shown in SEQ ID NO:2.

In a preferred embodiment the cell of the invention comprises at least one exogenous copy of a polynucleotide encoding MrgA protein or a functional homologue thereof comprising or consisting of the amino acid sequence shown in SEQ ID NO:2.

A preferred cell comprises at least one exogenous copy of a polynucleotide, which:

- a) comprises a polynucleotide sequence which is at least 70% identical to the sequence shown in SEQ ID NO:1; preferably at least 75%, 80%, 85%, 90%, 95%, 97%, or even 99% identical to the sequence shown in SEQ ID NO:1; or
- b) hybridizes with the sequence shown in SEQ ID NO:1, under medium stringency conditions, preferably under medium-high stringency, and more preferably under high stringency conditions.

As described above, and exemplified herein, one preferred embodiment relates to a cell, wherein at least one exogenous copy of a gene encoding the MrgA protein or a functional homologue thereof is transcribed from one or more heterologous and/or artificial promoter.

In a preferred cell, at least one exogenous copy of a gene encoding the MrgA protein or a functional homologue thereof is integrated into the genome of the cell; or is present on an extra-chromosomal construct, preferably a plasmid.

Another aspect of the invention relates to a method for enhancing secretion of an exoprotein of interest, the method comprising expressing said exoprotein in a cell according to the first aspect.

Still another aspect of the invention relates to a method for producing a cell as defined in the first aspect, useful for production of an exoprotein of interest, said method comprising a step of manipulating a cell to increase the expression of MrgA protein or functional homologue thereof.

In the production methods of the present invention, the cells are cultivated in a nutrient medium suitable for production of the polypeptide using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (e.g., in catalogues of the American Type Culture Collection). If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it can be recovered from cell lysates.

The polypeptides may be detected using methods known in the art that are specific for the polypeptides. These detection methods may include use of specific antibodies, formation of an enzyme product, or disappearance of an enzyme substrate. For example, an enzyme assay may be used to determine the activity of the polypeptide as described herein.

The polypeptides may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing), differential solubility (e.g., ammonium sulfate precipitation), SDS-PAGE, centrifugation, filtration, extraction, spray-drying, evaporation, precipitation, or extraction (see, e.g., Protein Purification, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).

In a preferred embodiment of the method of the third aspect, the manipulated cell secretes greater amounts of an exoprotein of interest than the non-manipulated parent cell.

Another preferred embodiment relates to the method of the third aspect, wherein said method comprises the steps of:

- a) identifying a gene from the parent cell that encodes MrgA protein or a functional homologue thereof; and
- b) manipulating the cell to increase the expression of the gene identified in step (a), whereby the manipulated progeny cell expresses greater amounts of MrgA protein or functional homologue thereof, than the non-manipulated cell.

EXAMPLES

Materials and Methods

Strains

B. subtilis 168: F. Kunst *et. al.* "The complete genome sequence of the Gram-positive bacterium *Bacillus subtilis*". Nature (1997) 390:249-256.

B. subtilis AN53: *B. subtilis* 168 with plasmid pKTH10 and P920mrgA integrated in the *amyE* locus (this study).

5 *B. subtilis* AN55: *B. subtilis* 168 with plasmid pKTH10 and P740mrgA integrated in the *amyE* locus (this study).

B. subtilis AN57: *B. subtilis* 168 with plasmid pKTH10 and P726mrgA integrated in the *amyE* locus (this study).

B. subtilis AN83: *B. subtilis* 168 with plasmid pKTH10 (this study).

10

Competent cells were prepared and transformed as described by Yasbin, R.E., Wilson, G.A. and Young, F.E. (1975) Transformation and transfection in lysogenic strains of *Bacillus subtilis* : evidence for selective induction of prophage in competent cells. J. Bacteriol, 121:296-304.

15

Plasmids

pKTH10: Vehmaanpera J, Steinborn G, Hofemeister J.: " Genetic manipulation of *Bacillus amyloliquefaciens*." J Biotechnol. 1991. 19(2-3):221-40. This plasmid constitutively express the *Bacillus amyloliquefaciens* alpha-amylase (AmyQ).

20 pDG268neo: This plasmid is a pDG268 derivative, which is unable to replicate in *Bacillus subtilis* (Antoniewski, C., Savelli, B., and Stragier, P., 1990, J. Bact 172). The plasmid contains the chloramphenicol (cam) resistance marker next to *SfiI* and *BamHI* restriction enzyme recognition sequences, flanked by the "5'" and "'3" portions of the *amyE* locus of *Bacillus subtilis*. This plasmid is used for introduction of the MrgA expression cassette and the cam marker into the *amyE* locus of *B. subtilis* via double homologous recombination cross-over.
25 The sequence of pDG268neo is shown in SEQ ID NO: 3.

p920mrgA: The *mrgA* gene was amplified by PCR from the chromosome of *B. subtilis* by use of primers p920mrgaF2 (SEQ ID NO: 4) and MBmrgaR2 (SEQ ID NO: 5). The upstream primer (p920mrgaF2; SEQ ID NO: 4) comprised a synthetic constitutive promoter, P920 (SEQ
30 ID NO: 6). The PCR product shown in SEQ ID NO: 7 was cut with restriction enzymes *SfiI* and *BamHI* and ligated to the large *SfiI*-*BamHI* fragment of pDG268neo, resulting in plasmid p920mrgA.

p740mrgA: The *mrgA* gene was amplified by PCR from the chromosome of *B. subtilis* by use of primers p740mrgaF2 (SEQ ID NO: 8) and MBmrgaR2 (SEQ ID NO: 5). The upstream
35 primer (p740mrgaF2; SEQ ID NO: 8) comprised a synthetic constitutive promoter, P740 (SEQ ID NO: 9). The PCR product shown in SEQ ID NO: 10 was cut with restriction enzymes *SfiI*

THIS PAGE BLANK (USPTO)

and *Bam*HI and ligated to the large *Sfi*I-*Bam*HI fragment of pDG268neo, resulting in plasmid p740mrgA.

p726mrgA: The *mrgA* was amplified by PCR from the chromosome of *B. subtilis* by use of primers p726mrgaF2 (SEQ ID NO: 11) and MBmrgaR2 (SEQ ID NO: 5). The upstream primer (p726mrgaF2; SEQ ID NO: 11) comprised the constitutive synthetic promoter P726 (SEQ ID NO: 12). The PCR product shown in SEQ ID NO: 13 was cut with restriction enzymes *Sfi*I and *Bam*HI and ligated to the large *Sfi*I-*Bam*HI fragment of pDG268neo, resulting in plasmid p726mrgA.

10 Primers:

P920mrgaF (SEQ ID NO: 4): ctgaggccaattaggccaagttattcttgacattaggggaacatgcatgatat
aataggtaaagtaaacagatcacaaggaggacgttattc

P740mrgaF (SEQ ID NO: 8): ctgaggccaattaggcccgaagttgttgacacagctccaggatacaaat
ataatgggtcgactaaacagatcacaaggaggacgttattc

15 P726mrgaF (SEQ ID NO: 11): ctgaggccaattaggccgaggtgagatttgacactagtaggctacgggac
tataatgcgggaagtaaacagatcacaaggaggacgttattc

MBmrgaR2 (SEQ ID NO: 5): tgaaggatccacgcgtccagcagacagaaagcag

General molecular biology methods

20 Unless otherwise mentioned the DNA manipulations and transformations were performed using standard methods of molecular biology (Sambrook et al. (1989) Molecular cloning: A laboratory manual, Cold Spring Harbor lab., Cold Spring Harbor, NY; Ausubel, F. M. et al. (eds.) "Current protocols in Molecular Biology". John Wiley and Sons, 1995; Harwood, C. R., and Cutting, S. M. (eds.) "Molecular Biological Methods for Bacillus". John Wiley and Sons, 25 1990).

Enzymes for DNA manipulations were used according to the specifications of the suppliers (e.g. restriction endonucleases, ligases etc. are obtainable from New England Biolabs, Inc.).

30 Media

LB agar (as described in Ausubel, F. M. et al. (eds.) "Current protocols in Molecular Biology". John Wiley and Sons, 1995).

LBP is LB agar supplemented with 0.05 M potassium phosphate, pH 7.0

LBPG is LB agar supplemented with 0.5% Glucose and 0.05 M potassium phosphate, pH 7.0.

35 LBPSK is LB agar supplemented with 0.05 M potassium phosphate, pH 7.0 and 1% of skimmed milk.

BPX media is described in EP 0 506 780 (WO 91/09129).

Fermentations

5 Fermentations to evaluate the amylase yields were performed in shakeflasks with 100 ml BPX at 37°C, 300 rpm for seven days. Culture volumes of 10 ml were harvested and centrifuged at 10.000 g to remove cells and debris. The clear supernants were used for assaying alpha-amylase activity.

Assay for alpha-amylase activity

10 Alpha-amylase activity was determined by a method employing an enzymatic colorimetric test with 4,6-ethylidene(G₇)-p-nitrophenyl(G₁)-alpha,D-maltoheptaoside (ethylidene-G₇PNP) as substrate (Boehringer Mannheim, Germany art. 1442309). Under a specified set of conditions (temp., pH, reaction time, buffer conditions) 1 mg of a given a-amylase will hydrolyse a certain amount of substrate and a yellow colour will be produced. The
15 colour intensity is measured at 405 nm. The measured absorbance is directly proportional to the activity of the alpha-amylase in question under a given set of conditions.

EXAMPLE 1

The *mrgA* gene was amplified by PCR from the chromosome of *B. subtilis* by use of
20 primers p920mrgaF2 (SEQ ID NO: 4) and MBmrgaR2 (SEQ ID NO: 5). The upstream primer (p920mrgaF2) comprised the constitutive synthetic promoter P920 (SEQ ID NO:6). The PCR product (SEQ ID NO: 7) was cut with restriction enzymes *SfiI* and *BamHI* and ligated to the large *SfiI*-*BamHI* fragment of pDG268neo, resulting in plasmid p920mrgA. The ligation-mixture of p920mrgA, described in the Material and Methods section, was introduced by transformation
25 into the *B. subtilis* 168 strain, and the transformants were plated on LBPSK media supplemented with 6 microg/ml chloramphenicol to select for integrants. Transformants growing on these plates have integrated the plasmid in the *amy* locus, either by a single (Cam⁺ kan⁺) or double cross-over event (cam⁺ kan⁺). Transformants were re-streaked on LBPSK/cam media with and without 20 microg/ml kanamycine. Strains where double cross-over events had
30 occurred were cam⁺ kan⁻. These strains no longer showed the tell-tale clearing zones; which signified that that integration in, and disruption of, the *amy* gene, had taken place. The site of integration and the *mrgA* sequence was verified by PCR and sequence analysis. The strain was transformed with plasmid pKTH10 which constitutively expresses the alpha-amylase AmyQ of *Bacillus amyloliquefaciens*. The resulting strain was named AN53. Yields of amylase
35 from AN53 were determined in triplicate from three independent isolates, and compared to the yield of amylase from the control strain AN83. Results are shown in table 1; the AN53 strain constitutively expressing *mrgA* from the synthetic promoter has an increased alpha-amylase

yield, which on average is 13% higher than the control strain, AN83, which only comprises a wild-type copy of the *mrgA* gene.

5 Table 1. Yields of amylase from AN53 were determined in triplicate from three independent isolates, and compared to the yield of amylase from the control strain AN83. The average yields of each strain are also shown. Nd: Not determined.

Strain	Amylase activity (relative)	average	average (in %)
AN53-1.1	15,7	13,5	113%
AN53-1.2	15,8		
AN53-1.3	14,9		
AN53-2.1	12,5		
AN53-2.2	8,65		
AN53-2.3	Nd		
AN53-3.1	Nd		
AN53-3.2	Nd		
AN53-3.3	Nd		
AN83-1.1	10,6	11,9	100%
AN83-1.2	15,7		
AN83-1.3	13,8		
AN83-2.1	8,7		
AN83-2.2	7,72		
AN83-2.3	10,1		
AN83-3.1	14,1		
AN83-3.2	Nd		
AN83-3.3	14,6		

10 **EXAMPLE 2**

The *mrgA* gene was amplified by PCR from the chromosome of *B. subtilis* by use of primers p740mrgaF2 (SEQ ID NO: 8) and MBmrgaR2 (SEQ ID NO: 5). The upstream primer (p740mrgaF2) comprised the constitutive synthetic promoter P740 (SEQ ID NO: 9). The PCR product (SEQ ID NO: 10) was cut with restriction enzymes *SfiI* and *BamHI*, and ligated to the large *SfiI*-*BamHI* fragment of pDG268neo, resulting in plasmid p740mrgA. The ligation-mixture of p740mrgA, described in the Material and Methods section, was introduced by transformation into the *B. subtilis* 168 strain, and the transformants were plated on LBPSK media supplemented with 6 microg/ml chloramphenicol (cam) to select for integrants. Transformants growing on these plates have integrated the plasmid in the *amy* locus, either by a single (Cam⁺ kan⁺) or double cross-over event (cam⁺ kan⁻). The transformants were re-streaked on LBPSK/cam media with and without 20 microg/ml kanamycine. Strains where double cross-over events had occurred were cam⁺ kan⁻. These strains no longer showed the tell-tale clearing zones; which signified that that integration in, and disruption of, the *amy* gene, had taken place. The site of integration and the *mrgA* sequence was verified by PCR and sequence

analysis. The resulting strain was transformed with plasmid pKTH10 which constitutively express the alpha-amylase AmyQ of *Bacillus amyloliquefaciens*. The resulting strain was named AN55. Yields of amylase from AN55 were determined in triplicate from three independent isolates, and compared to yield of amylase from the control strain AN83. Results are shown in table 2; the AN55 strain constitutively expressing *mrgA* from the synthetic promoter has an increased alpha-amylase yield, which on average is 21% higher than the control strain, AN83, which only comprises a wild-type copy of the *mrgA* gene.

Table 2. Yields of amylase from AN55 were determined in triplicate from three independent isolates, and compared to the yield of amylase from the control strain AN83. The average yields of each strain are also shown. Nd: Not determined.

Strain	Amylase activity (relative)	average	average (in %)
AN55-1.1	11,5	14,4	121%
AN55-1.2	10,8		
AN55-1.3	13,3		
AN55-2.1	17,4		
AN55-2.2	17,3		
AN55-2.3	15,6		
AN55-3.1	11,2		
AN55-3.2	14,8		
AN55-3.3	18,1		
AN83-1.1	10,6	11,9	100%
AN83-1.2	15,7		
AN83-1.3	13,8		
AN83-2.1	8,7		
AN83-2.2	7,72		
AN83-2.3	10,1		
AN83-3.1	14,1		
AN83-3.2	Nd		
AN83-3.3	14,6		

EXAMPLE 3

The *mrgA* gene was amplified by PCR from the chromosome of *B. subtilis* by use of primers p726mrgaF2 (SEQ ID NO: 11) and mrgaR2 (SEQ ID NO: 5). The upstream primer (p726mrgaF2) comprised the constitutive synthetic promoter P726 (SEQ ID NO: 12). The PCR product (SEQ ID NO: 13) was cut with restriction enzymes *Sfi*I and *Bam*HI and ligated to the large *Sfi*I-*Bam*HI fragment of pDG268neo, resulting in plasmid p726mrgA. The ligation-mixture of p726mrgA, described in the Material and Methods section, was introduced by transformation into the *B. subtilis* 168 strain, and the transformants were plated on LBPSK media supplemented with 6 microg/ml chloramphenicol to select for integrants. Transformants growing on these plates have integrated the plasmid in the *amy* locus, either by a single (Cam⁺

kan⁺) or double cross-over event (cam⁺ kan⁻). The transformants were then re-streaked on LBPSK/cam media with and without 20 microg/ml kanamycine. Strains where double cross-over events had occurred were cam⁺ kan⁻. These strains no longer showed the tell-tale clearing zones; which signified that that integration in, and disruption of, the *amy* gene, had taken place. The site of integration and the *mrgA* sequence was verified by PCR and sequence analysis. The resulting strain was then transformed with plasmid pKTH10, which constitutively express the alpha-amylase AmyQ of *Bacillus amyloliquefaciens*. The resulting strain was named AN57. Yields of amylase from AN57 were determined in triplicate from three independent isolates, and compared to the yield of amylase from the control strain AN83. Results are shown in table 3; the AN55 strain constitutively expressing *mrgA* from the synthetic promoter has an increased alpha-amylase yield, which on average is 40% higher than the control strain, AN83, which only comprises a wild-type copy of the *mrgA* gene.

Table 3. Yields of amylase from AN57 were determined in triplicate from three independent isolates, and compared to the yield of amylase from the control strain AN83. The average yields of each strain are also shown. Nd: Not determined.

Strain	Amylase activity (relative)	average	average (in %)
AN57-1.1	15,5	16,6	140%
AN57-1.2	10,6		
AN57-1.3	17,3		
AN57-2.1	17,4		
AN57-2.2	20,7		
AN57-2.3	13,9		
AN57-3.1	15,1		
AN57-3.2	17		
AN57-3.3	22		
AN83-1.1	10,6	11,9	100%
AN83-1.2	15,7		
AN83-1.3	13,8		
AN83-2.1	8,7		
AN83-2.2	7,72		
AN83-2.3	10,1		
AN83-3.1	14,1		
AN83-3.2	Nd		
AN83-3.3	14,6		

CLAIMS

1. A progeny cell derived from a parent cell, wherein

- a) the progeny cell comprises at least one gene encoding MrgA protein or a functional homologue thereof and/or a DNA segment operably linked with the encoding gene, wherein said gene and/or DNA segment is manipulated with respect to the parent cell;
- b) the progeny cell comprises two or more copies of a gene encoding MrgA protein or a functional homologue thereof; or
- c) the progeny cell is mutated with respect to the parent cell;

whereby the progeny cell produces greater amounts of MrgA protein or a functional homologue thereof than the parent cell.

2. The cell of claim 1, which secretes greater amounts of an exoprotein of interest than the parent cell.

3. The cell of claims 1 or 2, which is a bacterial cell, preferably a prokaryotic cell, more preferably a Gram-positive cell, and most preferably of the genus *Bacillus*.

4. The cell of claim 3, which is of a species chosen from the group consisting of *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*.

5. The cell of any of claims 2-4, wherein said exoprotein of interest is homologous or heterologous.

6. The cell of any of claims 2-5, wherein said exoprotein is a protease, a lipase, a cutinase, an amylase, a galactosidase, a pullulanase, a cellulase, a glucose isomerase, a protein disulphide isomerase, a CGTase (cyclodextrin gluconotransferase), a phytase, a glucose oxidase, a glucosyl transferase, lactase, bilirubin oxidase, a xylanase, an antigenic microbial or protozoan protein, a bacterial protein toxin, a microbial surface protein, or a viral protein.

7. The cell of any of claims 1-6, wherein the MrgA protein or functional homologue thereof comprises an amino acid sequence which is at least 70% identical to the amino sequence shown in SEQ ID NO:2, preferably at least 75%, 80%, 85%, 90%, 95%, 97%, or even 99% identical to the amino sequence shown in SEQ ID NO:2.

8. The cell of any of claims 1-7, wherein the MrgA protein or functional homologue thereof comprises the amino acid sequence shown in SEQ ID NO:2.
9. The cell of any of claims 1-8, which comprises at least one exogenous copy of a polynucleotide encoding MrgA protein or a functional homologue thereof comprising an amino acid sequence which is at least 70% identical to the amino sequence shown in SEQ ID NO:2, preferably at least 75%, 80%, 85%, 90%, 95%, 97%, or even 99% identical to the amino sequence shown in SEQ ID NO:2.
10. The cell of any of claims 1-9, which comprises at least one exogenous copy of a polynucleotide encoding MrgA protein or a functional homologue thereof comprising the amino acid sequence shown in SEQ ID NO:2.
11. The cell of any of claims 1-10, which comprises at least one exogenous copy of a polynucleotide, which:
- a) comprises a polynucleotide sequence which is at least 70% identical to the sequence shown in SEQ ID NO:1; preferably at least 75%, 80%, 85%, 90%, 95%, 97%, or even 99% identical to the sequence shown in SEQ ID NO:1; or
 - b) hybridizes with the sequence shown in SEQ ID NO:1, under medium stringency conditions, preferably under medium-high stringency, and more preferably under high stringency conditions.
12. The cell of any of claims 1-11, wherein at least one exogenous copy of a gene encoding the MrgA protein or a functional homologue thereof is transcribed from one or more heterologous and/or artificial promoter.
13. The cell of any of claims 1-12, wherein at least one exogenous copy of a gene encoding the MrgA protein or a functional homologue thereof is integrated into the genome of the cell.
14. The cell of any of claims 1-12, wherein at least one exogenous copy of a gene encoding the MrgA protein or a functional homologue thereof is present on an extra-chromosomal construct, preferably a plasmid.
15. A method for enhancing secretion of an exoprotein of interest, the method comprising expressing said exoprotein in a cell according to any of the preceding claims.

16. A method for producing a cell as defined in any of claims 1-14 useful for production of an exoprotein of interest, said method comprising a step of manipulating a cell to increase the expression of MrgA protein or functional homologue thereof.

17. The method of claim 16, wherein the cell secretes greater amounts of an exoprotein of interest than the non-manipulated parent cell.

18. The method of claims 16 or 17, wherein said method comprises the steps of:

- a) identifying a gene from the parent cell that encodes MrgA protein or a functional homologue thereof; and
- b) manipulating the cell to increase the expression of the gene identified in step (a), whereby the manipulated progeny cell expresses greater amounts of MrgA protein or functional homologue thereof, than the non-manipulated cell.

19. The method of any of claims 16-18, wherein the cell is a bacterial cell, preferably the cell is a prokaryotic cell, more preferably a Gram-positive cell, and most preferably the cell is of the genus *Bacillus*.

20. The method of claim 19, wherein the cell is of a species chosen from the group consisting of *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*.

21. The method of any of claims 16-20, wherein said exoprotein of interest is a protease, a lipase, a cutinase, an amylase, a galactosidase, a pullulanase, a cellulase, a glucose isomerase, a protein disulphide isomerase, a CGT'ase (cyclodextrin gluconotransferase), a phytase, a glucose oxidase, a glucosyl transferase, lactase, bilirubin oxidase, a xylanase, an antigenic microbial or protozoan protein, a bacterial protein toxin, a microbial surface protein, or a viral protein.

22. A method for producing an exoprotein of interest, comprising the steps of:

- a) cultivating a cell as defined in any of claims 2-14; and
- b) recovering the exoprotein.

23. The method of claim 22, wherein the cell is a bacterial cell, preferably the cell is a prokaryotic cell, more preferably a Gram-positive cell, and most preferably the cell is of the genus *Bacillus*.

24. The method of claim 23, wherein the cell is of a species chosen from the group consisting of *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*.

5

25. The method of any of claims 22-24, wherein said exoprotein of interest is a protease, a lipase, a cutinase, an amylase, a galactosidase, a pullulanase, a cellulase, a glucose isomerase, a protein disulphide isomerase, a CGT'ase (cyclodextrin gluconotransferase), a phytase, a glucose oxidase, a glucosyl transferase, lactase, bilirubin oxidase, a xylanase, an antigenic microbial or protozoan protein, a bacterial protein toxin, a microbial surface protein, or a viral protein.

10

26. Use of MrgA-protein or a functional homologue thereof in a method for enhancing secretion of an exoprotein by manipulating or mutating a cell to express greater amounts of MrgA protein or functional homologue thereof than the non-manipulated or non-mutated cell.

15

ABSTRACT

A progeny cell derived from a parent cell, wherein the progeny cell comprises at least one gene encoding MrgA protein or a functional homologue thereof and/or a DNA segment operably linked with the encoding gene, wherein said gene and/or DNA segment is

5 manipulated with respect to the parent cell; the progeny cell comprises two or more copies of a gene encoding MrgA protein or a functional homologue thereof; or the progeny cell is mutated with respect to the parent cell; whereby the progeny cell produces greater amounts of MrgA protein or a functional homologue thereof than the parent cell.

10 DEC. 2003

Modtaget

01 SQ Listing ST25 09-Dec-2003.txt
SEQUENCE LISTING

```

<110>  Novozymes A/S
<120>  A cell with improved secretion mediated by MrgA protein or
        homologue
<130>  10527.000-DK
<160>  13
<170>  PatentIn version 3.2
<210>  1
<211>  815
<212>  DNA
<213>  Bacillus subtilis 168

<220>
<221>  misc_feature
<222>  (201)..(659)
<223>  MrgA encoding sequence

<400>  1
aagaatttgc gatacccgat cggaaagggc atcaagctca ccctgctggt ccgatcgctt      60
tttccttggt ctgcgtggga gtctatcctg aagaaaaagc tattcagctg atctaaatta      120
taattattat aatttagtat tgatttttat ttagtatatg atataattaa gtcaacagat      180
cacaaggagg acgttatctt atgaaaactg aaaacgcaaa aacaaatcaa acattagttg      240
agaattcact gaacacacaa ttatcaaact ggtttctttt atactctaag ctccaccggt      300
tccattggta tgtgaaaggg cctcatttct ttacattgca cgagaaattt gaagaacttt      360
atgaccatgc ggctgaaaca gtggatacca tcgctgagcg cctgctggcg attggcggac      420
agcctgttgc cacagtgaag gaatacactg agcatgcatc tatcacagac ggcggaaacg      480
aaacatcagc atcagaaatg gtacaagcat tggtaaacga ctacaaacaa atcagcagcg      540
aatctaaatt cgtgatcggc ctggctgaag aaaatcaaga caatgcgaca gcggacttgt      600
ttgtcggatt aattgaagaa gttgaaaaac aagtgtggat gctttcctct tatttagggg      660
aacaaaaaag ctgaacctta atcgggttca gctttttggt ttttccttagc ttgaactgct      720
ttctgtctgc ttggtcagtg ttgcgttcaa cgttttcggt tttccctttc gcagcacttg      780
gattgttggt ttatctccga cttttaagtc tttgt                                     815

<210>  2
<211>  153
<212>  PRT
<213>  Bacillus subtilis 168

<220>
<221>  PEPTIDE
<222>  (1)..(153)
<223>  MrgA protein

<400>  2

```

Met Lys Thr Glu Asn Ala Lys Thr Asn Gln Thr Leu Val Glu Asn Ser

1 5 10 15
 Leu Asn Thr Gln Leu Ser Asn Trp Phe Leu Leu Tyr Ser Lys Leu His
 20 25 30
 Arg Phe His Trp Tyr Val Lys Gly Pro His Phe Phe Thr Leu His Glu
 35 40 45
 Lys Phe Glu Glu Leu Tyr Asp His Ala Ala Glu Thr Val Asp Thr Ile
 50 55 60
 Ala Glu Arg Leu Leu Ala Ile Gly Gly Gln Pro Val Ala Thr Val Lys
 65 70 75 80
 Glu Tyr Thr Glu His Ala Ser Ile Thr Asp Gly Gly Asn Glu Thr Ser
 85 90 95
 Ala Ser Glu Met Val Gln Ala Leu Val Asn Asp Tyr Lys Gln Ile Ser
 100 105 110
 Ser Glu Ser Lys Phe Val Ile Gly Leu Ala Glu Glu Asn Gln Asp Asn
 115 120 125
 Ala Thr Ala Asp Leu Phe Val Gly Leu Ile Glu Glu Val Glu Lys Gln
 130 135 140
 Val Trp Met Leu Ser Ser Tyr Leu Gly
 145 150

<210> 3
 <211> 8644
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Plasmid pDG268neo

<400> 3
 aacaaaattc tccagtcttc acatcggttt gaaaggagga agcgggaagaa tgaagtaaga 60
 gggatttttg actccgaagt aagtcttcaa aaaatcaaat aaggagtgtc aagaatgttt 120
 gcaaaacgat tcaaaacctc tttactgccg ttattcgctg gattttttatt gctgtttcat 180
 ttggttctgg caggaccggc ggctgcgag* gctgcaaacg cgaacaaatc gaatgagctt 240
 acagcaccgt cgatcaaaaag cggaaccatt cttcatgcat ggaattgggtc gttcaatacg 300
 ttaaaacaca atatgaagga tattcatgat gcaggatata cagccattca gacatctccg 360
 attaaccaag taaaggaagg gaatcaagga gataaaagca tgtcgaactg gtactggctg 420
 tatcagccga catcgtatca aattggcaac cgttacttag gtactgaaca agaatttaaa 480
 gaaatgtgtg cagccgctga agaatatggc ataaagggtca ttgttgacgc gcggccgcgg 540
 atccatacac aaaaaaacgc tgtgcccttt aaccgcacag cgttttttta ttgattaacg 600

01 SQ Listing ST25 09-Dec-2003.txt

cggtgccgct	tctgcgtaa	caagtcgct	tccatacaag	ttcgtgcttc	ctaaactagt	660
tgccgtattc	tttagatgat	ttcgaatttg	tacattagac	caagatgggt	tcttttgttt	720
aacaagggcg	gccgcacctg	caacatgagg	agtagccatc	gatgtaccgt	ttaagctggc	780
atatgttgaa	cctgggtatg	tgctctgcac	gtttaccccg	gggtgcgaaa	tgtcaaggcc	840
tgcgccatac	tgtgaaaagc	tagcgcgggt	gttgttttga	tcagtagctc	cgactgccat	900
tgcgttcgca	tagcgcgcgg	gatacttgat	tgagcctgca	cctgaattcc	cagatgccgc	960
tacaacaaga	acgcctctag	aagtcgcgct	attaacagct	tgctcgagtg	tggcacttgg	1020
cgaagggctt	cctaaactca	aattagcaac	gtgcatgcc	ttgttccctg	cccattccaa	1080
tccttgggca	atcgagctga	ccgaacctga	accgctcgcc	cctaggactt	taacagcgta	1140
tagctcagcg	ctcggcgcta	cgccaagaac	gccaatcgaa	ttgtttaaag	cagcgatcgt	1200
cccggccaca	tgcgtgccat	gcccattccc	atcttgagtc	gacggttccc	ctggtacaaa	1260
gcttgcgcca	ccacgaatat	ttagatctgg	atgagtggat	atccctgtat	cgaggacagc	1320
aacttttaca	ccagaacctg	tcaatccacg	gttatgggca	gctggggctt	gcacacggct	1380
aattccccat	ggtaccgatt	gcgccattgt	cgttacttct	gcatcctctt	caatataaga	1440
aatcgctgga	tcgagttcaa	gcgcgtccac	atcttctggg	cttaactcaa	cggataaaaac	1500
aggaatcggt	tcaaattcat	gaagcaattc	aatttcgact	tcctcttcct	cagagagaat	1560
ggcgacctcg	tcatttgcct	ctacttgttc	tacaaactca	ctgacagctt	cctgctcatt	1620
aaagccaatt	aaatattttt	cttttgcttc	ttcagcagcc	gatgcgatcg	atgaactaaa	1680
agcaacagaa	atgagtagtg	cggtgcttgc	gacaattttc	cccaacgggt	tcttcattcg	1740
gtttccctcc	tcatttttat	agagctccat	aatacataat	tttcaaactg	ataaaatgat	1800
ttttcataaa	tccattagac	gggtgcaaata	tatgttttta	atgttcttcg	tttttaggca	1860
tccctccttt	caagataaat	aatttatata	ctattctatt	ggaatcttaa	tcattccaat	1920
agaaaaatat	gtaatgatta	taaataagtc	gcttcttata	ataaatatat	ttacatatct	1980
atttaatact	acatcatgtt	aggtatagta	aggctatcaa	gggtgtctta	atttctactt	2040
gtaacaatgt	attggcatat	tatatattga	attgagaaaa	ttaaatacag	cgataattca	2100
catgaacaag	ttcattggta	gttatatttt	caaattttca	aggttggtgt	tgtatgtcat	2160
tctatagtta	gataagcatt	tgaggtagag	tccgtccgaa	tatatattga	atctgaagaa	2220
ggttcaaaca	tatttctata	taacgtattc	tttttttgta	gttcttactt	ttgagggggcg	2280
ttacaattca	aagatattat	ctttaattaa	gcttaacatt	aataattctt	caattgcaac	2340
aaaaaaaagca	cttttatcta	aggtttcatc	ttacgtttcg	agggcccttc	cattttctta	2400
tacaaattat	attatacata	tcagtaaaaat	aatgtcaacc	cccctttatt	cctttttttt	2460
acacagcgga	cagtctggac	agcaggccct	taaggccaat	tctcatgttt	gacagcttat	2520
catcggaat	agttaccctt	attatcaaga	taagaaagaa	aaggattttt	cgctacgctc	2580
aaatccttta	aaaaaacaca	aaagaccaca	ttttttaatg	tggtctttat	tcttcaacta	2640

01 SQ Listing ST25 09-Dec-2003.txt

aagcacccat tagttcaaca aacgaaaatt ggataaagtg ggatattttt aaaatatata	2700
tttatgttac agtaatatg acttttaaaa aaggattgat tctaataag aaagcagaca	2760
agtaagcctc cttaaattcac tttagataaa aatttaggag gcataatcaa tgaactttaa	2820
taaaattgat ttagacaatt ggaagagaaa agagatatatt aatcattatt tgaaccaaca	2880
aacgactttt agtataacca cagaaattga tattagtgtt ttataaccgaa acataaaaaca	2940
agaaggatat aaattttacc ctgcatttat tttcttagtg acaagggta taaactcaaa	3000
tacagctttt agaactggtt acaatagcga cggagagtta gggtattggg ataagttaga	3060
gccactttat acaatttttg atgggtgatac taaaacattc tctggatttt ggactcctgt	3120
aaagaatgac ttcaaagagt tttatgattt atacctttct gatgtagaga aatataatgg	3180
ttcggggaaa ttgtttccca aaacacctat acctgaaaat gctttttctc tttctattat	3240
tccatggact tcattttactg ggtttaactt aaatatcaat aataatagta attaccttct	3300
accattatt acagcaggaa aattcattaa taaaggtaat tcaatatatt taccgctatc	3360
tttacaggta catcattctg tttgtgatgg ttatcatgca ggattgttta tgaactctat	3420
tcaggaattg tcagataggc ctaatgactg gcttttataa tatgagataa tgccgactgt	3480
actttttaca gtcgggtttc taatgtcact aacctgcccc gttagttgaa gaaggttttt	3540
atattacagc tccagatcct ctacgccgga cgcctcgtgg ccggcatcac cggcgccaca	3600
gggtgcggttg ctggcgccca tatcgccgac atcaccgatg gggaagatcg ggctcgccac	3660
ttcgggctca tgagcgcttg tttcggcgtg ggtatggtgg caggccccgt ggccggggga	3720
ctgttgggcg ccatctcctt gcatgcacca ttccttgccg cggcgggtgct caacggcctc	3780
aacctactac tgggctgctt cctaattgcag gagtcgcata agggagagcg tcgacatgga	3840
tgagcgatga tgatatccgt ttaggctggg cgggtgatagc ttctcgttca ggcagtacgc	3900
ctcttttctt ttccagacct gagggaggcg gaaatggtgt gaggttcccg gggaaaagcc	3960
aaataggcga tcgcgggagt gctttatttg aagatcaggc tatcactgcg gtcaatagat	4020
ttcacaatgt gatggctgga cagcctgagg aactctcgaa cccgaatgga aacaaccaga	4080
tatttatgaa tcagcgcggc tcacatggcg ttgtgctggc aaatgcaggt tcctcctctg	4140
tctctatcaa tacggcaaca aaattgcctg atggcaggta tgacaataaa gctggagcgg	4200
gttcatttca agtgaacgat ggtaaactga caggcacgat caatgccagg tctgtagctg	4260
tgctttatcc tgatgatatt gcaaaagcgc ctcatgtttt ccttgagaat tacaaaacag	4320
gtgtaacaca ttctttcaat gatcaactga cgattacctt gcgtgcagat gcgaatacaa	4380
caaagaccgt ttatcaaatac aataatggac cagacgacag gcgtttaagg atggagatca	4440
attcacaatc ggaaaaggag atccaatttg gcaaaacata caccatcatg ttaaaaggaa	4500
cgaacagtga tgggtgaacg aggaccgaga aatacagttt tgttaaaaga gatccagcgt	4560
cggccaaaac catcggctat caaaatccga atcattggag ccaggtaaat gcttatatct	4620
ataaacatga tgggagccga gtaattgaat tgaccggatc ttggcctgga aaaccaatga	4680

01_SQ_Listing_ST25_09-Dec-2003.txt

ctaaaaatgc agacggaatt	tacacgctga cgctgcctgc	ggacacggat acaaccaacg	4740
caaaagtgat ttttaataat	ggcagcgccc aagtgcccg	tcagaatcag cctggctttg	4800
attacgtgct aaatggttta	tataatgact cgggcttaag	cggttctctt cccattgag	4860
ggcaaggcta gacgggactt	accgaaagaa accatcaatg	atggtttctt ttttgttcat	4920
aaatcagaca aaacttttct	cttgcaaaaag tttgtgaagt	gttgacacaat ataaatgtga	4980
aatacttcac aaacaaaaag	acatcaaaga gaaacatacc	ctgcaaggat gctgatattg	5040
tctgcatttg cgccggagca	aacaaaaaac ctggtgagac	acgccttgaa ttagtagaaa	5100
agaacttgaa gattttcaaa	ggcatcgta gtgaagtc	ggcagcgga tttgacggca	5160
ttttcttagt cggtacaat	cctcgtaaa ggacaaggac	ctgagcgga gtgtatcgta	5220
cagtagacgg agtatactag	tatagtctat agtcctgga	attattatat ttatctccga	5280
cgatattctc atcagtga	aaa tccagctgga gttctttagc	aaatTTTTTT attagctgaa	5340
cttagtatta gtggggccgc	tgataattac taatactagg	agaagttaat aaatacgtaa	5400
ccaacatgat taacaattat	tagaggtcac cgttcaaaat	ggtatgcgtt ttgacacatc	5460
cactatatat ccgtgtcgtt	ctgtccactc ctgaatccca	ttccagaaat tctctagcga	5520
ttccagaagt ttctcagagt	cggaaagttg accagacatt	acgaactggc acagatggtc	5580
ataacctgaa ggaagatctg	attgcttaac tgcttcagtt	aagaccgaag cgctcgtcgt	5640
ataacagatg cgatgatgca	gaccaatcaa catggcacct	gccattgcta cctgtacagt	5700
caaggatggg agaaatgttg	tcggtccttg cacacgaata	ttacgccatt tgcctgcata	5760
ttcaaacagc tcttctacga	taagggcaca aatcgcacg	tggaacgttt gggcttctac	5820
cgatttagca gtttgataca	ctttctctaa gtatccacct	gaatcataaa tcggcaaaat	5880
agagaaaaat tgaccatgtg	taagcggcca atctgattcc	acctgagatg cataatctag	5940
tagaatctct tcgctatcaa	aattcacttc caccttcac	tcaccggttg tccattcatg	6000
gctgaactct gcttcctctg	ttgacatgac acacatcatc	tcaatatccg aatagggcc	6060
atcagtctga cgaccaagag	agccataaac accaatagcc	ttaacatcat ccccatattt	6120
atccaatatt cgttccttaa	tttcatgaac aatcttcatt	ctttcttctc tagtcattat	6180
tattggtcca ttcactattc	tcattccctt ttcagataat	tttagatttg cttttctaaa	6240
taagaatatt tggagagcac	cgttcttatt cagctattaa	taactcgtct tcctaagcat	6300
catgattctc cttttccact	ttttgtcttg tccacataaa	cccttgattt ttcatctgaa	6360
taaatgctac tattaggaca	cataatatta aaagaaaccc	ccatctattt agttatttgt	6420
ttagtcactt ataactttaa	cagatggggg ttttctgtgc	aaccaatttt aagggttttc	6480
aatactttaa aacacataca	taccaacact tcaacgcacc	tttcagcaac taaaataaaa	6540
atgacgttat ttctatatgt	atcaagataa gaaagaacaa	gttcaaaacc atcaaaaaaa	6600
gacacctttt caggtgcttt	ttttatttta taaactcatt	ccctgatctc cccatactcc	6660
tccaatccaa agctatttag	aaagattact atatcctcaa	acaggcggta accggcctct	6720

01 SQ Listing ST25 09-Dec-2003.txt

tcatacgggaa	tgcgcgcgcac	cttcagcatc	gccggcatgt	ccccctggcg	gacgggaagt	6780
atccagctcg	aggtcgggccc	gcgttgctgg	cgtttttcca	taggctccgc	ccccctgacg	6840
agcatcacia	aaatcgacgc	tcaagtcaga	ggtggcgaaa	cccgacagga	ctataaagat	6900
accaggcggt	tccccctgga	agctccctcg	tgcgctctcc	tgttccgacc	ctgccgctta	6960
ccggatacct	gtccgccttt	ctcccttcgg	gaagcgtggc	gctttctcat	agctcacgct	7020
gtaggtatct	cagttcggtg	taggtcgttc	gctccaagct	gggctgtgtg	cacgaacccc	7080
ccgttcagcc	cgaccgctgc	gccttatccg	gtaactatcg	tcttgagtcc	aacccggtaa	7140
gacacgactt	atcgccactg	gcagcagcca	ctggtaacag	gattagcaga	gcgaggtatg	7200
taggcgggtg	tacagagttc	ttgaagtgg	ggcctaacta	cggctacact	agaaggacag	7260
tatttggtat	ctgcgctctg	ctgaagccag	ttaccttcgg	aaaaagagtt	ggtagctctt	7320
gatccggcaa	acaaaccacc	gctggtagcg	gtgggttttt	tgtttgcaag	cagcagatta	7380
cgcgcagaaa	aaaaggatct	caagaagatc	ctttgatctt	ttctacgggg	tctgacgctc	7440
agtggaaacga	aaactcacgt	taagggattt	tggtcatgag	attatcaaaa	aggatcttca	7500
cctagatcct	tttaaattaa	aaatgaagtt	ttaaatcaat	ctaaagtata	tatgagtaaa	7560
cttggtctga	cagttacca	tgcttaata	gtgaggcacc	tatctcagcg	atctgtctat	7620
ttcggtcatc	catagttgcc	tgactccccg	tcgtgtagat	aactacgata	cgggagggct	7680
taccatctgg	ccccagtgt	gcaatgatac	cgcgagaccc	acgctcaccg	gctccagatt	7740
tatcagcaat	aaaccagcca	gccggaaggg	ccgagcgcag	aagtggctct	gcaactttat	7800
ccgcctccat	ccagtctatt	aattgttgcc	gggaagctag	agtaagtagt	tcgccagtta	7860
atagtttgcg	caacgttggt	gccattgctg	caggcatcgt	ggtgtcacgc	tcgtcgtttg	7920
gtatggcttc	attcagctcc	ggttcccaac	gatcaaggcg	agttacatga	tccccatgt	7980
tgtgcaaaaa	agcggtttagc	tccttcgggtc	ctccgatcgt	tgtcagaagt	aagttggccg	8040
cagtgttatc	actcatgggt	atggcagcac	tgcataattc	tcttactgtc	atgccatccg	8100
taagatgctt	ttctgtgact	ggtgagtact	caaccaagtc	attctgagaa	tagtgtatgc	8160
ggcgaccgag	ttgtctttgc	ccggcgtaaa	cacgggataa	taccgcgcca	catagcagaa	8220
ctttaaaagt	gctcatcatt	ggaaaacgtt	cttcggggcg	aaaactctca	aggatcttac	8280
cgctgttgag	atccagttcg	atgtaaccca	ctcgtgcacc	caactgatct	tcagcatctt	8340
ttactttcac	cagcgtttct	gggtgagc	caaaaatgcc	gcaaaaaagg		8400
gaataagggc	gacacggaaa	tgttgaatac	tcataactctt	cctttttcaa	tattattgaa	8460
gcaatttatca	gggttattgt	ctcatgagcg	gatacatatt	tgaatgtatt	tagaaaaata	8520
aacaaatagg	ggttccgcgc	acatttcccc	gaaaagtgcc	acctgacgtc	taagaaacca	8580
ttattatcat	gacattaacc	tataaaaata	ggcgtatcac	gaggcccttt	cgtcttcaag	8640
aatt						8644

01 SQ Listing ST25 09-Dec-2003.txt

```

<211> 91
<212> DNA
<213> Artificial sequence

<220>
<223> Primer p920mrgaF2

<400> 4
ctgaggccaa ttaggccaaag tttattcttg acattagga acatgcatga tataataggt 60
aaagtaaaca gatcacaagg aggacgttat c 91

<210> 5
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Primer MBmrgaR2

<400> 5
tgaaggatcc acgcgtccag cagacagaaa gcag 34

<210> 6
<211> 49
<212> DNA
<213> Artificial sequence

<220>
<223> Promoter P920

<400> 6
aagtttattc ttgacattag ggaacatgca tgatataata ggtaaagta 49

<210> 7
<211> 642
<212> DNA
<213> Artificial sequence

<220>
<223> PCR product of promoter 920 and mrgA

<400> 7
ctgaggcctt aagggccaag tttattcttg acattagga acatgcatga tataataggt 60
aaagtaaaca gatcacaagg aggacgttat cttatgaaaa ctgaaaacgc aaaaacaaat 120
caaacattag ttgagaattc actgaacaca caattatcaa actggtttct tttatactct 180
aagctccacc gtttccattg gtatgtgaaa gggcctcatt tctttacatt gcacgagaaa 240
tttgaagaac tttatgacca tgcggctgaa acagtggata ccatcgctga gcgcctgctg 300
gcgattggcg gacagcctgt tgccacagtg aaagaatata ctgagcatgc atctatcaca 360
gacggcggaa acgaaacatc agcatcagaa atggtacaag cattggtaaa cgactacaaa 420
caaatcagca gcgaatctaa attcgtgatc ggcctggctg aagaaaatca agacaatgcg 480
acagcggact tgtttgctcg attaattgaa gaagttgaaa aacaagtgtg gatgctttcc 540
tcttatttag ggtaacaaaa aagctgaacc ttaatcgggt tcagcttttt gttttttctt 600
agcttgaact gctttctgtc tgcttgacgc gtggatcctt ca 642

```


<210> 8
 <211> 91
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Primer p740mrgaF2

<400> 8 60
 ctgaggccaa ttaggcccgg aagtttggtg acacagctcc aggatacaaa tataatgggt
 91
 cgactaaaca gatcacaagg aggacgttat c

<210> 9
 <211> 49
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Promoter P740

<400> 9 49
 cggaagtttg ttgacacagc tccaggatac aaatataatg ggtcagagta

<210> 10
 <211> 642
 <212> DNA
 <213> Artificial sequence

<220>
 <223> PCR product of promoter 740 and mrgA

<400> 10 60
 ctgaggcctt aagggcccg aagtttggtg acacagctcc aggatacaaa tataatgggt
 120
 cgagtaaaca gatcacaagg aggacgttat cttatgaaaa ctgaaaacgc aaaaacaaat
 180
 caaacattag ttgagaattc actgaacaca caattatcaa actggtttct tttatactct
 240
 aagctccacc gtttccattg gtatgtgaaa gggcctcatt tctttacatt gcacgagaaa
 300
 tttgaagaac tttatgacca tgccgctgaa acagtggata ccatcgctga gcgcctgctg
 360
 gcgattggcg gacagcctgt tgccacagtg aaagaatata ctgagcatgc atctatcaca
 420
 gacggcggaa acgaaacatc agcatcagaa atgggtacaag cattggtaaa cgactacaaa
 480
 caaatcagca gcgaatctaa attcgtgatc ggcctggctg aagaaaatca agacaatgcg
 540
 acagcggact tgtttgctcg attaattgaa gaagttgaaa aacaagtgtg gatgctttcc
 600
 tcttatttag ggtaacaaaa aagctgaacc ttaatcgggt tcagcttttt gttttttctt
 642
 agcttgaact gctttctgtc tgcttgacgc gtggatcctt ca

<210> 11
 <211> 91
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Primer p726mrgaF2

<400> 11

01 SQ Listing ST25 09-Dec-2003.txt
ctgaggccaa ttaggccgag gtgagatttg acactagtag gctacgggac tataatgcgg 60
gaagtaaaca gatcacaagg aggacgttat c 91

<210> 12
<211> 49
<212> DNA
<213> Artificial sequence

<220>
<223> Promoter P726

<400> 12
gaggtgagat ttgacactag taggctacgg gactataatg cggaagta 49

<210> 13
<211> 642
<212> DNA
<213> Artificial sequence

<220>
<223> PCR product of promoter P726 and mrgA

<400> 13
ctgaggcctt aagggccgag gtgagatttg acactagtag gctacgggac tataatgcgg 60
gaagtaaaca gatcacaagg aggacgttat cttatgaaaa ctgaaaacgc aaaaacaaat 120
caaacattag ttgagaattc actgaacaca caattatcaa actggtttct ttataactct 180
aagctccacc gtttccattg gtatgtgaaa gggcctcatt tctttacatt gcacgagaaa 240
tttgaagaac tttatgacca tgcggctgaa acagtggata ccatcgctga gcgctgctg 300
gcgattggcg gacagcctgt tgccacagtg aaagaatata ctgagcatgc atctatcaca 360
gacggcggaa acgaaacatc agcatcagaa atggtacaag cattggtaaa cgactacaaa 420
caaatcagca gcgaatctaa attcgtgatc ggcctggctg aagaaaatca agacaatgcg 480
acagcggact tgtttgtcgg attaatgaa gaagttgaaa aacaagtgtg gatgctttcc 540
tcttatttag ggtaacaaaa aagctgaacc ttaatcgggt tcagcttttt gttttttctt 600
agcttgaact gctttctgtc tgcttgacgc gtggatcctt ca 642

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/DK04/000859

International filing date: 10 December 2004 (10.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: DK
Number: PA 2003 01824
Filing date: 10 December 2003 (10.12.2003)

Date of receipt at the International Bureau: 14 January 2005 (14.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.